Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

FDA Grants Fast Track Designation to ARV-110 for mCRPC

May 30th 2019

The FDA has granted a fast track designation to ARV-110, a PROTAC® protein degrader, for use as a treatment of patients with metastatic castration-resistant prostate cancer who have disease progression following ≥2 systemic therapies.

PARP Inhibition Appears Promising in CRPC, But Questions Remain

May 17th 2019

PARP inhibitors alone and in combinations are demonstrating potential in castration-resistant prostate cancer, but questions about survival benefit, toxicities, and efficacy remain to be answered.

Dr. McGregor on Data Evaluating the Link Between Cardiac Complications and ADT in Prostate Cancer

May 15th 2019

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the data behind the potential link between cardiac complications and androgen deprivation therapy (ADT) in prostate cancer.

ADT-Associated Cardiac AEs in Prostate Cancer Require Multidisciplinary Care

May 10th 2019

Pei-Chun McGregor, MD, discusses where future research with androgen deprivation therapy-associated adverse events is headed, and called for multidisciplinary care for patients receiving this approach.

Rapid Advances Underscore Significance of Patient Selection in Metastatic Prostate Cancer

May 9th 2019

Atish D. Choudhury, MD, PhD, details the advances in metastatic prostate cancer in light of updated analyses from several clinical trials and forthcoming research in the field.

Pivotal Studies Pave Way for Nonmetastatic CRPC Treatment

May 8th 2019

Richard (Rick) JaeBong Lee, MD, PhD, discusses the differences between second-generation targeted antiandrogens and highlights potential factors to consider in terms of selection.

Dr. Higano on the Toxicity of Androgen Receptor Inhibitors in CRPC

May 7th 2019

Celestia Higano, MD, FACP, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, professor, Department of Medicine and Urology, University of Washington, Seattle Cancer Care Alliance, discusses the toxicity of androgen receptor inhibitors in castration-resistant prostate cancer.

Novel Imaging Techniques Emerge in Prostate Cancer

May 6th 2019

David J. Einstein, MD, discusses newer imaging techniques and overall progress in the treatment of patients with nonmetastatic hormone-sensitive prostate cancer.

Dr. Einstein on Biochemical Recurrence in Prostate Cancer

May 4th 2019

David J. Einstein, MD, instructor of medicine at Harvard Medical School, and attending physician of medicine at Beth Israel Deaconess Medical Center, discusses biochemical recurrence in patients with prostate cancer.

FDA Approval Sought for Apalutamide in Metastatic Castration-Sensitive Prostate Cancer

April 30th 2019

A supplemental new drug application has been submitted to the FDA for the approval of apalutamide (Erleada) for use as a treatment of patients with metastatic castration-sensitive prostate cancer.

FDA Grants Priority Review to Darolutamide in Nonmetastatic CRPC

April 29th 2019

The FDA has granted a priority review designation to a new drug application for darolutamide for use as a treatment for patients with nonmetastatic castration-resistant prostate cancer.

Updated Screening Guidelines in Prostate Cancer

April 27th 2019

MaryBeth Freeman, MPH, senior associate scientist, Surveillance Research, American Cancer Society, discusses updated screening guidelines in prostate cancer.

Comprehensive Urology Care Does Not Mean Sacrificing Community Connection

April 24th 2019

Implementation of an integrated practice model, in which in-house and outside referrals are available, has enabled Garden State Urology to continue to provide patients with high standards of care while maintaining the familiarity of a community style clinic.

Avoiding Urologist Burnout

April 23rd 2019

For the urologist who feels overworked and overstretched, paradigm-shifting advances may represent an opportunity to stave off burnout, more effectively use clinical acumen gained over the years, and maintain practice engagement.

Dr. Gomella on the Prevalence of Genetic Testing in Prostate Cancer

April 19th 2019

Leonard G. Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the prevalence of genetic testing in prostate cancer.

Gomella Calls for Increased Genetic Testing in Prostate Cancer

April 18th 2019

Leonard G. Gomella, MD, underscores the need for genetic testing in prostate cancer, sheds light on important biomarkers in the space, and explains how these tests are helping oncologists facilitate a precision medicine approach.

Dr. Gieschen on Toxicities Associated With Radiation Therapy in Prostate Cancer

April 17th 2019

Holger L. Gieschen, MD, assistant professor, University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the toxicities associated with radiation therapy in prostate cancer.

Dr. Slovin on Avoiding ADT-Associated Cardiac Complications in Prostate Cancer

April 17th 2019

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses ways to avoid androgen deprivation therapy (ADT)-associated cardiac complications in patients with prostate cancer.

Fee-for-Service Unlikely to Disappear Soon

April 15th 2019

Fee-for-service tends to result in a surplus of care and unnecessary medical expense, but it probably won’t disappear from the landscape soon.

Enzalutamide/Docetaxel Combo Improves PFS, But Not OS in Frontline mCRPC

April 8th 2019

Orazio Caffo, MD, discusses the CHEIRON trial findings and their implications on the treatment paradigm in metastatic castration-resistant prostate cancer.